DOCSLIB.ORG

Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission R ICHARD A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission R ICHARD A Chapter 11 Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission R ICHARD A. GLENNON AND MAŁGORZATA DUKAT Drugs Covered in This Chapter* Antiemetic drugs (5-HT3 receptor • Rizatriptan • Imipramine antagonists) • Sumatriptan • Olanzapine • Alosetron • Zolmitriptan • Propranolol • Dolasetron Drug for the treatment of • Quetiapine • Granisetron irritable bowel syndrome (5-HT4 • Risperidone • Ondansetron agonists) • Tranylcypromine • Palonosetron • Tegaserod • Trazodone • Tropisetron Drugs for the treatment of • Ziprasidone Drugs for the treatment of neuropsychiatric disorders • Zotepine migraine (5-HT1D/1F receptor agonists) • Buspirone Hallucinogenic agents • Almotriptan • Citalopram • Lysergic acid diethylamide • Eletriptan • Clozapine • 2,5-dimethyl-4-bromoamphetamine • Frovatriptan • Desipramine • 2,5-dimethoxy-4-iodoamphetamine • Naratriptan • Fluoxetine Abbreviations cAMP, cyclic adenosine IBS-C, irritable bowel syndrome with nM, nanomoles/L monophosphate constipation MT, melatonin CNS, central nervous system IBS-D, irritable bowel syndrome with MTR, melatonin receptor 5-CT, 5-carboxamidotryptamine diarrhea NET, norepinephrine reuptake transporter DOB, 2,5-dimethyl-4-bromoamphetamine LCAP, long-chain arylpiperazine 8-OH DPAT, 8-hydroxy-2-(di-n- DOI, 2,5-dimethoxy-4-iodoamphetamine L-DOPA, L-dihydroxyphenylalanine propylamino)tetralin EMDT, 2-ethyl-5-methoxy-N,N- LSD, lysergic acid diethylamide PMDT, 2-phenyl-5-methoxy-N,N- dimethyltryptamine MAO, monomaine oxidase dimethyltryptamine GABA, g-aminobutyric acid MAOI, monoamine oxidase inhibitor SAFIR, structure–affinity relationship 5-HT, serotonin mCPBG, m-chlorophenylbiguanide SAR, structure–activity relationship 5-HTP, 5-hydroxytryptophan mCPG, m-chlorophenylguanidine SERT, serotonin transporter IBS, irritable bowel syndrome mCPP, m-chlorophenylpiperazine SSRI, selective serotonin reuptake inhibitor *Drugs available outside the U.S. are shown in italics. 365 LLemke_Chap11.inddemke_Chap11.indd 336565 112/9/20112/9/2011 22:23:14:23:14 AAMM 366 PART II / DRUG RECEPTORS AFFECTING NEUROTRANSMISSION AND ENZYMES AS CATALYTIC RECEPTORS SCENARIO Jill T. Johnson, PharmD, BCPS MB is a 34-year-old woman with migraines. She experiences pho- aura. After using sumatriptan for several months, taking it rou- tophobia and severe headaches with nausea and vision changes tinely up to 300 mg per day for 15 days of the month, she real- about twice per month. Recently she was prescribed sumatriptan ized it was not working as well as it had been. to take as abortive therapy once she begins to feel the migraine SEROTONIN United States, the substance was called serotonin, whereas in Italy, it was termed enteramine. Its total Serotonin could be considered the “baby boomer” of synthesis in the early 1950s confirmed that both sub- neurotransmitters: It was fi rst identifi ed in the late stances were the same structure: 5-hydroxytryptamine 1940s, its adolescent years were troubled, it made the (5-HT). Serotonin (5-HT) was later detected in numer- drug scene in the 1960s, and it nearly died of an over- ous plant and animal species, and in the mid-1950s, dose in the early 1970s. It could be considered the it was identified in the central nervous system (CNS) original “sex, drugs, and rock-and-roll” receptor (as will of animals. A neurotransmitter role was proposed. be described below [see also Chapter 19], serotonin 5-HT was implicated in a variety of central and periph- receptors have been implicated in sexual behavior, eral physiologic actions. It seemed to be involved in drug abuse [especially that involving classical halluci- vasoconstriction and vasodilation, regulation of body nogens], and the perception of sound)—but, it does temperature, sleep, and hormonal regulation, and much more. early evidence suggested that it could be involved in At one time, it was remarked that “serotonin doesn’t depression. The structural similarity between 5-HT do anything” (1). On reaching its middle years, sero- tonin matured and became an important topic of study, a household name, and more complicated than ever. Serotonin has been associated with, among TABLE 11.1 Some Indications and Treatment Claims other things, anxiety, depression, schizophrenia, drug for Novel Serotonergic Agents in the abuse, sleep, dreaming, hallucinogenic activity, head- Patent Literature ache, cardiovascular disorders, sexual behavior, and appetite control. Television ads now routinely refer to Aggression Esophagitis Obsessive-compulsive serotonin and serotonin receptor antagonists. This, disorders subsequently, prompted the comment that “it almost Alcoholism Gastric motility Pain appears that serotonin is involved in everything” (1). A review of the current patent literature provides Alzheimer’s disease Head injury Panic disorders an indication of some of the claims being made for serotonergic agents (Table 11.1). Tens of thousands Amnesia Headache Parkinson’s disease of papers have been published on serotonin. Much Anorexia Hypertension Psychosis is known—but an incredible amount remains to be learned. Bulimia Impotence Raynaud’s disease Cardiac failure Irritable bowel Schizophrenia N O syndrome OH Cardiovascular Ischemia Sedation H NH2 N disorders CH3 Cerebrovascular Migraine Sexual dysfunction N N disorders H H Cognition disorders Movement Sleep disorders Serotonin (5-HT) (+)-Lysergic acid diethylamide (LSD) Depression Nausea Substance abuse Drug abuse Neurodegenerative Substance dependence A hormonal substance was independently identi- disease fied in the late 1940s by two groups of investigators, Emesis Obesity Thromboembolism one in the United States and the other in Italy. In the LLemke_Chap11.inddemke_Chap11.indd 336666 112/9/20112/9/2011 22:23:15:23:15 AAMM CHAPTER 11 / SEROTONIN RECEPTORS AND DRUGS AFFECTING SEROTONERGIC NEUROTRANSMISSION 367 CLINICAL SIGNIFICANCE Discovery of the different types Unfortunately, they also may cause coronary vasoconstric- of serotonin receptors during tion, making them contraindicated in patients with underlying the past few years has created coronary artery disease. Antagonists of the 5-HT3 receptor, the potential to target these recep- ondansetron, and granisetron, work to lessen emesis in che- tors. Altering the chemical structures may motherapy-induced and radiation-associated emesis as well as improve tolerability, reduce the risk of side effects, improve postoperative nausea and vomiting. A variety of drugs work to efficacy, enhance compliance, or simply provide an alternative inhibit selective serotonin reuptake without acting on any spe- drug should another in the class fail to provide relief for a given cific serotonin receptor. Drugs such as fluoxetine, paroxetine, patient. sertraline, and fluvoxamine have been effective in the treatment The clinical effects of serotonin receptors are multifaceted. At of depression, obsessive-compulsive disorder, and panic disorder this time, only a few of the identified receptors have drugs that with varying degrees of side effects like weight gain, weight loss, are currently marketed for use in humans. Buspirone stimulates and drowsiness. the 5-HT1A receptor to cause antianxiety effects. The 5-HT1D Jill T. Johnson, Pharm.D., BCPS agonists, or the “triptans,” vary by side chains on essentially the Associate Professor same core structure to create compounds with different affinities Department of Pharmacy Practice for the 5-HT1D receptors and, likely, for other serotonin recep- College of Pharmacy tors as well. The varying affinities of each triptan for receptors University of Arkansas for Medical Science change the profiles of their effectiveness and adverse or compli- Little Rock, AR mentary effects. As a rule, the triptans work to treat migraine headaches by causing vasoconstriction. and the then recently discovered hallucinogenic agent Serotonin Biosynthesis, Catabolism, and Function (+)-lysergic acid diethylamide (LSD) intrigued investi- as Targets for Drug Manipulation gators. The observation led to speculation that 5-HT 5-HT is biosynthesized from its dietary precursor l-trypto- could be involved in the mechanism of action of this phan (5) (Fig. 11.1). Serotonergic neurons contain trypto- psychoactive substances and could also have a role in phan hydroxylase (l-tryptophan-5-monooxygenase) that certain mental disorders. LSD was shown to behave as converts tryptophan to 5-hydroxytryptophan (5-HTP), in a potent 5-HT receptor agonist in certain peripheral what is the rate-limiting step in 5-HT biosynthesis, and aro- receptor assays and as a potent antagonist in others. matic l-amino acid decarboxylase (a nonselective decar- The late 1960s and early 1970s, however, witnessed a boxylase previously called 5-HTP decarboxylase) that decline in 5-HT research as the result of three factors: decarboxylates 5-HTP to 5-HT. This latter enzyme is also 1) sophisticated experimental techniques were still responsible for the conversion of l-dihydroxyphenylala- lacking for the investigation of the central actions of nine (l-DOPA) to dopamine (see Chapter 13). The major 5-HT; 2) apart from ergolines (LSD-related agents), route of metabolism of 5-HT is oxidative deamination only a few potent 5-HT agonists or antagonists had by monoamine oxidase (MAO; specifi cally, by MAO-A) been developed; and 3) it was becoming increasingly to the unstable 5-hydroxyindole-3-acetaldehyde, which is difficult to understand how a single putative neu- either reduced to 5-hydroxytryptophol (∼15%) or to the rotransmitter substance could be involved in so many oxidized
Load more

Recommended publications
  • Severe Organophosphate Poisoning with Delayed Cholinergic Crisis, Intermediate Syndrome and Organophosphate Induced Delayed Polyneuropathy on Succession
    Organophosphate Poisoning… Aklilu A 203 CASE REPORT SEVERE ORGANOPHOSPHATE POISONING WITH DELAYED CHOLINERGIC CRISIS, INTERMEDIATE SYNDROME AND ORGANOPHOSPHATE INDUCED DELAYED POLYNEUROPATHY ON SUCCESSION Aklilu Azazh ABSTRACT Organophosphate compounds are the organic derivatives of Phosphorous containing acids and their effect on neuromuscular junction and Autonomic Synapses is clinically important. After exposure these agents cause acute and sub acute manifestations depending on the type and severity of the agents like Acute Cholinergic Manifestations, Intermediate Syndrome with Nicotinic features and Delayed Central Nervous System Complications. The patient reported here had severe Organophosphate Poisoning with various rare complications on a succession. This is the first report of Organophosphates Poisoning complicated by Intermediate Syndrome and Organophosphate Induced Delayed Polyneuropathy in Ethiopia and it is reported to increase awareness of health care workers on these rare complications of a common problem. INTRODUCTION phosphorylated by the Phosphate end of Organophosphates; then the net result is Organophosphate compounds are the organic accumulation of excessive Acetyl Chlorine with derivatives of Phosphorous containing acids and resultant effect on Muscarinic, Nicotinic and their effect on Neuromuscular Junction and central nervous system (Figure 2). Autonomic synapses is clinically important. In the Neuromuscular Junction Acetylcholine is released Following classical OP poisoning, three well when a nerve impulse reaches
    [Show full text]
  • Molecular Signatures of G-Protein-Coupled Receptors A
    REVIEW doi:10.1038/nature11896 Molecular signatures of G-protein-coupled receptors A. J. Venkatakrishnan1, Xavier Deupi2, Guillaume Lebon1,3,4,5, Christopher G. Tate1, Gebhard F. Schertler2,6 & M. Madan Babu1 G-protein-coupled receptors (GPCRs) are physiologically important membrane proteins that sense signalling molecules such as hormones and neurotransmitters, and are the targets of several prescribed drugs. Recent exciting developments are providing unprecedented insights into the structure and function of several medically important GPCRs. Here, through a systematic analysis of high-resolution GPCR structures, we uncover a conserved network of non-covalent contacts that defines the GPCR fold. Furthermore, our comparative analysis reveals characteristic features of ligand binding and conformational changes during receptor activation. A holistic understanding that integrates molecular and systems biology of GPCRs holds promise for new therapeutics and personalized medicine. ignal transduction is a fundamental biological process that is comprehensively, and in the process expand the current frontiers of required to maintain cellular homeostasis and to ensure coordi- GPCR biology. S nated cellular activity in all organisms. Membrane proteins at the In this analysis, we objectively compare known structures and reveal cell surface serve as the communication interface between the cell’s key similarities and differences among diverse GPCRs. We identify a external and internal environments. One of the largest and most diverse consensus structural scaffold of GPCRs that is constituted by a network membrane protein families is the GPCRs, which are encoded by more of non-covalent contacts between residues on the transmembrane (TM) than 800 genes in the human genome1. GPCRs function by detecting a helices.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression
    Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder.
    [Show full text]
  • FDA Warns About an Increased Risk of Serious Pancreatitis with Irritable Bowel Drug Viberzi (Eluxadoline) in Patients Without a Gallbladder
    FDA warns about an increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder Safety Announcement [03-15-2017] The U.S. Food and Drug Administration (FDA) is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, we are working with the Viberzi manufacturer, Allergan, to address these safety concerns. Patients should talk to your health care professional about how to control your symptoms of irritable bowel syndrome with diarrhea (IBS-D), particularly if you do not have a gallbladder. The gallbladder is an organ that stores bile, one of the body’s digestive juices that helps in the digestion of fat. Stop taking Viberzi right away and get emergency medical care if you develop new or worsening stomach-area or abdomen pain, or pain in the upper right side of your stomach-area or abdomen that may move to your back or shoulder. This pain may occur with nausea and vomiting. These may be symptoms of pancreatitis, an inflammation of the pancreas, an organ important in digestion; or spasm of the sphincter of Oddi, a muscular valve in the small intestine that controls the flow of digestive juices to the gut. Health care professionals should not prescribe Viberzi in patients who do not have a gallbladder and should consider alternative treatment options in these patients.
    [Show full text]
  • Therapeutic Class Overview Irritable Bowel Syndrome Agents
    Therapeutic Class Overview Irritable Bowel Syndrome Agents Therapeutic Class Overview/Summary: This review will focus on agents used for the treatment of Irritable Bowel Syndrome (IBS).1-5 IBS is a gastrointestinal syndrome characterized primarily by non-specific chronic abdominal pain, usually described as a cramp-like sensation, and abnormal bowel habits, either constipation or diarrhea, in which there is no organic cause. Other common gastrointestinal symptoms may include gastroesophageal reflux, dysphagia, early satiety, intermittent dyspepsia and nausea. Patients may also experience a wide range of non-gastrointestinal symptoms. Some notable examples include sexual dysfunction, dysmenorrhea, dyspareunia, increased urinary frequency/urgency and fibromyalgia-like symptoms.6 IBS is defined by one of four subtypes. IBS with constipation (IBS-C) is the presence of hard or lumpy stools with ≥25% of bowel movements and loose or watery stools with <25% of bowel movements. When IBS is associated with diarrhea (IBS-D) loose or watery stools are present with ≥25% of bowel movements and hard or lumpy stools are present with <25% of bowel movements. Mixed IBS (IBS-M) is defined as the presence of hard or lumpy stools with ≥25% and loose or water stools with ≥25% of bowel movements. Final subtype, or unsubtyped, is all other cases of IBS that do not fall into the other classes. Pharmacological therapy for IBS depends on subtype.7 While several over-the-counter or off-label prescription agents are used for the treatment of IBS, there are currently only two agents approved by the Food and Drug Administration (FDA) for the treatment of IBS-C and three agents approved by the FDA for IBS-D.
    [Show full text]
  • What Are the Acute Treatments for Migraine and How Are They Used?
    2. Acute Treatment CQ II-2-1 What are the acute treatments for migraine and how are they used? Recommendation The mainstay of acute treatment for migraine is pharmacotherapy. The drugs used include (1) acetaminophen, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans and (5) antiemetics. Stratified treatment according to the severity of migraine is recommended: use NSAIDs such as aspirin and naproxen for mild to moderate headache, and use triptans for moderate to severe headache, or even mild to moderate headache when NSAIDs were ineffective in the past. It is necessary to give guidance and cautions to patients having acute attacks, and explain the methods of using medications (timing, dose, frequency of use) and medication use during pregnancy and breast-feeding. Grade A Background and Objective The objective of acute treatment is to resolve the migraine attack completely and rapidly and restore the patient’s normal functions. An ideal treatment should have the following characteristics: (1) resolves pain and associated symptoms rapidly; (2) is consistently effective; (3) no recurrence; (4) no need for additional use of medication; (5) no adverse effects; (6) can be administered by the patients themselves; and (7) low cost. Literature was searched to identify acute treatments that satisfy the above conditions. Comments and Evidence The acute treatment drugs for migraine generally include (1) acetaminophens, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans, and (5) antiemetics. For severe migraines including status migrainosus and migraine attacks refractory to treatment, (6) anesthetics, and (7) corticosteroids (dexamethasone) are used (Tables 1 and 2).1)-9) There are two approaches to the selection and sequencing of these medications: “step care” and “stratified care”.
    [Show full text]
  • Management of Chronic Problems
    MANAGEMENT OF CHRONIC PROBLEMS INTERACTIONS BETWEEN ALCOHOL AND DRUGS A. Leary,* T. MacDonald† SUMMARY concerned. Alcohol may alter the effects of the drug; drug In western society alcohol consumption is common as is may change the effects of alcohol; or both may occur. the use of therapeutic drugs. It is not surprising therefore The interaction between alcohol and drug may be that concomitant use of these should occur frequently. The pharmacokinetic, with altered absorption, metabolism or consequences of this combination vary with the dose of elimination of the drug, alcohol or both.2 Alcohol may drug, the amount of alcohol taken, the mode of affect drug pharmacokinetics by altering gastric emptying administration and the pharmacological effects of the drug or liver metabolism. Drugs may affect alcohol kinetics by concerned. Interactions may be pharmacokinetic or altering gastric emptying or inhibiting gastric alcohol pharmacodynamic, and while coincidental use of alcohol dehydrogenase (ADH).3 This may lead to altered tissue may affect the metabolism or action of a drug, a drug may concentrations of one or both agents, with resultant toxicity. equally affect the metabolism or action of alcohol. Alcohol- The results of concomitant use may also be principally drug interactions may differ with acute and chronic alcohol pharmacodynamic, with combined alcohol and drug effects ingestion, particularly where toxicity is due to a metabolite occurring at the receptor level without important changes rather than the parent drug. There is both inter- and intra- in plasma concentration of either. Some interactions have individual variation in the response to concomitant drug both kinetic and dynamic components and, where this is and alcohol use.
    [Show full text]
  • Intramuscular Tramadol Vs. Diclofenac Sodium for The
    J Headache Pain (2005) 6:143–148 DOI 10.1007/s10194-005-0169-y ORIGINAL Zulfi Engindeniz Intramuscular tramadol vs. diclofenac sodium Celaleddin Demircan Necdet Karli for the treatment of acute migraine attacks Erol Armagan in emergency department: a prospective, Mehtap Bulut Tayfun Aydin randomised, double-blind study Mehmet Zarifoglu Received: 6 February 2005 Abstract The aim of this prospec- injection in future visits. Any Accepted in revised form: 15 April 2005 tive, randomised, double-blind study adverse events, whether related to Published online: 13 May 2005 was to evaluate the efficacy of intra- the drug or not, were also recorded. muscular (IM) tramadol 100 mg in Patients were followed up by tele- emergency department treatment of phone 48 h later to check for any acute migraine attack and to com- headache recurrence. Two-hour pain pare it with that of IM diclofenac response rate, which was the prima- sodium 75 mg. Forty patients who ry endpoint, was 80% for both tra- were admitted to our emergency madol and diclofenac groups. There department with acute migraine were no statistically significant dif- attack according to the International ferences among groups in terms of Z. Engindeniz (౧) • E. Armagan • M. Bulut Headache Society criteria were 48-h pain response, rescue treat- T. Aydin Department of Emergency Medicine, included in the study. Patients were ment, associated symptoms’ Uludag University Medical Faculty, randomised to receive either tra- response, headache recurrence and Acil Tip ABD Gorukle, madol 100 mg (n=20) or diclofenac adverse event rates. Fifteen (75%) Bursa 16059, Turkey sodium 75 mg (n=20) intramuscular- patients in the tramadol group and e-mail: [email protected] ly.
    [Show full text]
  • Protocol for a Randomised Controlled Trial: Efficacy of Donepezil Against
    BMJ Open: first published as 10.1136/bmjopen-2013-003533 on 25 September 2013. Downloaded from Open Access Protocol Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson’s disease (EDAP) Hideyuki Sawada, Tomoko Oeda To cite: Sawada H, Oeda T. ABSTRACT ARTICLE SUMMARY Protocol for a randomised Introduction: Psychosis, including hallucinations and controlled trial: efficacy of delusions, is one of the important non-motor problems donepezil against psychosis Strengths and limitations of this study in patients with Parkinson’s disease (PD) and is in Parkinson’s disease ▪ In previous randomised controlled trials for (EDAP). BMJ Open 2013;3: possibly associated with cholinergic neuronal psychosis the efficacy was investigated in patients e003533. doi:10.1136/ degeneration. The EDAP (Efficacy of Donepezil against who presented with psychosis and the primary bmjopen-2013-003533 Psychosis in PD) study will evaluate the efficacy of endpoint was improvement of psychotic symp- donepezil, a brain acetylcholine esterase inhibitor, for toms. By comparison, this study is designed to prevention of psychosis in PD. ▸ Prepublication history for evaluate the prophylactic effect in patients this paper is available online. Methods and analysis: Psychosis is assessed every without current psychosis. Because psychosis To view these files please 4 weeks using the Parkinson Psychosis Questionnaire may be overlooked and underestimated it is visit the journal online (PPQ) and patients with PD whose PPQ-B score assessed using a questionnaire, Parkinson (http://dx.doi.org/10.1136/ (hallucinations) and PPQ-C score (delusions) have Psychosis Questionnaire (PPQ) every 4 weeks. bmjopen-2013-003533). been zero for 8 weeks before enrolment are ▪ The strength of this study is its prospective randomised to two arms: patients receiving donepezil design using the preset definition of psychosis Received 3 July 2013 hydrochloride or patients receiving placebo.
    [Show full text]
  • The Neuroprotective Effects of Melatonin: Possible Role in the Pathophysiology of Neuropsychiatric Disease
    brain sciences Perspective The Neuroprotective Effects of Melatonin: Possible Role in the Pathophysiology of Neuropsychiatric Disease Jung Goo Lee 1,2 , Young Sup Woo 3, Sung Woo Park 2,4, Dae-Hyun Seog 5, Mi Kyoung Seo 6 and Won-Myong Bahk 3,* 1 Department of Psychiatry, College of Medicine, Haeundae Paik Hospital, Inje University, Busan 47392, Korea; [email protected] 2 Paik Institute for Clinical Research, Department of Health Science and Technology, Graduate School, Inje University, Busan 47392, Korea; [email protected] 3 Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul 07345, Korea; [email protected] 4 Department of Convergence Biomedical Science, College of Medicine, Inje University, Busan 47392, Korea 5 Department of Biochemistry, College of Medicine, Inje University, Busan 47392, Korea; [email protected] 6 Paik Institute for Clinical Research, Inje University, Busan 47392, Korea; [email protected] * Correspondence: [email protected] Received: 16 September 2019; Accepted: 19 October 2019; Published: 21 October 2019 Abstract: Melatonin is a hormone that is secreted by the pineal gland. To date, melatonin is known to regulate the sleep cycle by controlling the circadian rhythm. However, recent advances in neuroscience and molecular biology have led to the discovery of new actions and effects of melatonin. In recent studies, melatonin was shown to have antioxidant activity and, possibly, to affect the development of Alzheimer’s disease (AD). In addition, melatonin has neuroprotective effects and affects neuroplasticity, thus indicating potential antidepressant properties. In the present review, the new functions of melatonin are summarized and a therapeutic target for the development of new drugs based on the mechanism of action of melatonin is proposed.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]